Lysine

Lysine

SCHEMBL9767908

Cl.NCCCC[C@H](N)C(=O)[O-].NCCCC[C@H](N)C(=O)[O-].[Zn+2]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.59
GNAI3 P08754 1/20 0.42
GNAO1 P09471 1/20 0.42
GNAI1 P63096 1/20 0.42
RNPEP Q9H4A4 1/20 0.42
DPP7 Q9UHL4 9/20 0.41
DPP8 Q6V1X1 5/20 0.41
DPP9 Q86TI2 5/20 0.41
DPP4 P27487 3/20 0.41
CPB2 Q96IY4 2/20 0.38
ARG2 P78540 1/20 0.38
BLM P54132 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
FAP Q12884 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL1034337 0.98 GSR (0.61) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL3739868 0.98 GSR (0.61) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL30634517 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL9767745 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL27663119 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL9767655 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL9767768 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL9767819 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL10620093 0.96 GSR (0.59) GSRGNAI3GNAO1GNAI1RNPEP
Lysine SCHEMBL12470732 0.94 GSR (0.57) GSRGNAI3GNAO1GNAI1RNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4021437-A1 IMPROVING, MAINTAINING, PROTECTING AND REPAIRING TISSUE INTEGRITY, BARRIER FUNCTION AND IMMUNITY USING A COMPOSITION COMPRISING A SOURCE OF ZINC IONS Colgate-Palmolive Company (US) 2022-07-06 EP claimed
WO-2021203132-A1 IMPROVING, MAINTAINING, PROTECTING AND REPAIRING TISSUE INTEGRITY, BARRIER FUNCTION AND IMMUNITY USING A COMPOSITION COMPRISING A SOURCE OF ZINC IONS COLGATE-PALMOLIVE COMPANY (US) 2021-10-07 WO claimed
US-20210308028-A1 Compositions and Methods for Maintaining and Protecting Tissue Integrity and Barrier Function COLGATE-PALMOLIVE COMPANY (US) 2021-10-07 US claimed
US-20160296437-A1 ORAL CARE ZINC COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2016-10-13 US claimed
EP-3076921-A1 ORAL CARE ZINC COMPOSITIONS Colgate-Palmolive Company (US) 2016-10-12 EP claimed
WO-2015084314-A1 ORAL CARE ZINC COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2015-06-11 WO claimed
EP-4021437-A1 IMPROVING, MAINTAINING, PROTECTING AND REPAIRING TISSUE INTEGRITY, BARRIER FUNCTION AND IMMUNITY USING A COMPOSITION COMPRISING A SOURCE OF ZINC IONS Colgate-Palmolive Company (US) 2022-07-06 EP disclosed
WO-2021203132-A1 IMPROVING, MAINTAINING, PROTECTING AND REPAIRING TISSUE INTEGRITY, BARRIER FUNCTION AND IMMUNITY USING A COMPOSITION COMPRISING A SOURCE OF ZINC IONS COLGATE-PALMOLIVE COMPANY (US) 2021-10-07 WO disclosed
US-20210308028-A1 Compositions and Methods for Maintaining and Protecting Tissue Integrity and Barrier Function COLGATE-PALMOLIVE COMPANY (US) 2021-10-07 US disclosed
CN-111214388-A Oral care zinc compositions 高露洁-棕榄公司 2020-06-02 CN disclosed
EP-3076921-B1 ORAL CARE ZINC COMPOSITIONS COLGATE PALMOLIVE CO (US) 2020-03-04 EP disclosed
US-9943473-B2 Zinc lysine halide complex COLGATE-PALMOLIVE COMPANY (US) 2018-04-17 US disclosed
US-9925130-B2 Composition with zinc amino acid/trimethylglycine halide precursors COLGATE-PALMOLIVE COMPANY (US) 2018-03-27 US disclosed
US-20150328095-A1 COMPOSITION WITH ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE PRECURSORS COLGATE-PALMOLIVE COMPANY (US) 2015-11-19 US disclosed
EP-2934439-A1 COMPOSITION WITH ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE PRECURSORS Colgate-Palmolive Company (US) 2015-10-28 EP disclosed
EP-2934438-A1 ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE Colgate-Palmolive Company (US) 2015-10-28 EP disclosed
WO-2015084314-A1 ORAL CARE ZINC COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2015-06-11 WO disclosed
WO-2014098814-A1 COMPOSITION WITH ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE PRECURSORS COLGATE-PALMOLIVE COMPANY (US) 2014-06-26 WO disclosed
WO-2014098813-A1 ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE COLGATE-PALMOLIVE COMPANY (US) 2014-06-26 WO disclosed
US-5061815-A Dietary supplementation ZINPRO CORPORATION (US) 1991-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150328095-A1 COMPOSITION WITH ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE PRECURSORS ZFX, SLC39A3, SLC39A11 GSR 969/4885GNAI3 2490/4885GNAO1 2555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.